Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from pharmacy benefit managers. Such insurers are often erecting obstacles to reimbursement, like steep price restrictions and approval processes that limit user access. Industr